
## CLAIMS

1. A compound of Formula I:



(**I**)

or a pharmaceutically acceptable salt thereof;

wherein:

A and A' are each, independently, CH, $CR^8$, or N;

W and Z are each, independently, N, CH, C-halo, C-($C_1$-$C_3$ alkyl), or C-($C_1$-$C_3$ alkoxy);

X and Y are each, independently, N, CH, or $CR^3$;

provided that at least one of W, X, Y, or Z is CH;

$R^1$ is selected from the group consisting of 6-10 membered aryl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, and 3-10 membered cycloalkyl, all of which are optionally substituted with one, two, or three $R^8$;

$R^2$ is selected from the group consisting of 6-10 membered aryl, 5-10 membered heteroaryl, 3-10 membered heterocycloalkyl, and 3-10 membered cycloalkyl, all of which are optionally substituted with one, two, or three $R^6$;

$R^3$ is independently, at each occurrence, selected from the group consisting of halogen, $OR^4$, $NR^4R^4$, $SO_2R^4$, $SO_2NHR^4$, $NHSO_2R^4$, $C(O)OR^4$, $C(O)NHR^4$, $C(O)R^4$, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, 3-7 membered cycloalkyl, $C_4$-$C_7$ cycloalkenyl, $C_6$-$C_{10}$ aryl, 5-6 membered heteroaryl, and 5-7 membered heterocyclyl, wherein alkyl, alkenyl, or alkynyl are each optionally substituted one, two, or three times with $R^4$, and wherein aryl, heteroaryl, or heterocyclyl are each optionally substituted one, two, or three times with $R^5$;

$R^4$ is independently, at each occurrence, selected from the group consisting of H, $(CH_2)_{0-3}$-($C_3$-$C_7$ cycloalkyl), $(CH_2)_{0-3}$-($C_4$-$C_7$ cycloalkenyl), $(CH_2)_{0-3}$-($C_6$-$C_{10}$ aryl), $(CH_2)_{0-3}$-(5-6 membered heteroaryl), and $(CH_2)_{0-3}$-(5-7 membered heterocyclyl), wherein the aryl, heteroaryl, or heterocyclyl are each optionally substituted one, two, or three times with $R^5$;

$R^5$ is independently, at each occurrence, selected from the group consisting of $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, $C_1$-$C_3$ alkylamine, 3-10 membered cycloalkyl, halogen, COOH, C(O)O($C_1$-$C_6$ alkyl), O$(CH_2)_{1-3}$-OH, $NH_2$, NH($C_1$-$C_6$ alkyl), N($C_1$-$C_6$ alkyl)$_2$, OH, CN, $(CH_2)_{0-3}$-($C_6$-$C_{10}$ aryl), $(CH_2)_{0-3}$-(5-6 membered heteroaryl), and $(CH_2)_{0-3}$-(5-7 membered heterocyclyl), wherein the aryl, heteroaryl, or heterocyclyl are each optionally substituted one, two, or three times with $R^7$;

$R^6$ is independently, at each occurrence, selected from the group consisting of $C_1$-$C_3$ alkyl, $C_1$-$C_3$ haloalkyl, $C_1$-$C_3$ alkoxy, $C_1$-$C_3$ haloalkoxy, $C_1$-$C_3$ alkylamine, halogen, OH, $NO_2$, $NH_2$, $NH(C_1$-$C_6$ alkyl), $N(C_1$-$C_6$ alkyl)$_2$, $(CH_2)_{1-4}OH$, $S(O)_{0-2}H$, $S(O)_{0-2}NH_2$, or CN;


alternatively, two $R^6$, together with the atoms to which they are attached, can form 5-10 membered heteroaryl, 6-10 membered aryl, 3-10 membered heterocycloalkyl, or 3-10 membered cycloalkyl;

$R^7$ is independently, at each occurrence, selected from the group consisting of substituents independently selected from $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, $C_1$-$C_6$ alkoxy, $C_1$-$C_6$ haloalkoxy, halogen, $NH_2$, $NH(C_1$-$C_6$ alkyl), $N(C_1$-$C_6$ alkyl)$_2$, $SO_2NH_2$, $SO_2NH(C_1$-$C_6$ alkyl), $SO_2N(C_1$-$C_6$ alkyl)$_2$, $(CH_2)_{1-2}$-OH, $C(O)(CH_2)_{1-2}$-OH, $C(O)(C_1$-$C_6$ alkyl), and $C(O)O(C_1$-$C_6$ alkyl);

alternatively, two $R^7$, together with the atoms to which they are attached, can form 5-10 membered heteroaryl, 6-10 membered aryl, 3-10 membered heterocycloalkyl, or 3-10 membered cycloalkyl; and

$R^8$ is independently, at each occurrence, selected from the group consisting of $C_1$-$C_3$ alkyl, $C_1$-$C_3$ haloalkyl, $C_1$-$C_3$ alkoxy, $C_1$-$C_3$ haloalkoxy, $C_1$-$C_3$ alkylamine, 3-6 membered cycloalkyl, halogen, OH, $NO_2$, $NH_2$, $NH(C_1$-$C_6$ alkyl), $N(C_1$-$C_6$ alkyl)$_2$, $(CH_2)_{1-4}OH$, $S(O)_{0-2}H$, $S(O)_{0-2}NH_2$, or CN.

2. The compound of claim 1, wherein the compound of Formula I is a compound of Formula Ia:




(**Ia**)


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein Z is CF.

4. The compound of any one of claims 1-3, wherein $R^6$ is independently, at each occurrence, hydroxy or halo.


5. The compound of any one of claims 1-4, wherein $R^1$ is selected from the group consisting of benzimidazole, imidazopyrazine, purine, imidazole, pyrazole, triazole, and imidazopyridine.











6. The compound of any one of claims 1-4, wherein $R^1$ is selected from the group consisting of:












and ;


all of which are optionally substituted with one, two, or three $R^8$.

7. The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of



| | |
|---|---|
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

| | |
|---|---|
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |




or a pharmaceutically acceptable salt thereof.

8. The compound of any one of claims 1-6, wherein $R^7$ is $C_1$-$C_3$ alkyl.

9. The compound of any one of claims 1-6, and 8, wherein W is CH.


10. The compound of any one of claims 1-6, 8, and 9, wherein $R^3$ is phenyl substituted one time with piperidine, wherein piperidine is substituted one time with $R^7$.

11. The compound of any one of claims 1-6, and 8-10, wherein the compound of Formula I is


;

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 11, wherein the compound of Formula I is


;

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound of any one the preceding claims, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

14. Use of a compound or pharmaceutical composition of any one of the preceding claims in the manufacture of a medicament for the treatment of cancer.

15. The use according to claim 14, wherein the cancer is selected from the group consisting of lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, and prostate cancer.

16. The use according to claim 14, wherein the cancer is non-small cell lung cancer (NSCLC).

17. The use according to any one of claims 14-16, wherein the medicament further comprises osimertinib.

18. The use according to any one of claims 14-16, wherein the medicament is for co-administration with a therapeutically effective amount of osimertinib.